| 2025 | 2024 | 2023 | ||||
|---|---|---|---|---|---|---|
| Gross margin | 300,0 k € | +8.6% | 276,3 k € | -7.4% | 298,5 k € | |
| EBITDA | 11,1 k € | +205.3% | -10,5 k € | -128.4% | 37,1 k € | |
| Operating profit | 9,2 k € | +173.6% | -12,5 k € | -136.3% | 34,5 k € | |
| Profit/loss | 9,2 k € | +183.7% | -11,0 k € | -133.3% | 32,9 k € | |
| Equity | 809,7 k € | +1.1% | 800,6 k € | -1.4% | 811,5 k € | |
| Total assets | 1,7 M € | +0.6% | 1,7 M € | +22.8% | 1,3 M € | |
| Cash | 832,1 k € | -15.4% | 983,3 k € | -4.9% | 1,0 M € | |
| Debts | 172,3 k € | +88.4% | 91,4 k € | +20.9% | 75,6 k € | |
Non-profit organization · Woluwe-Saint-Lambert · incorporated on 28/11/2019
Non-profit organization profitable and well capitalised. Cash position declining (-15.4%).
Solid counterparty for a standard engagement.
Key indicators
Cancer Drug Development Forum is a Non-profit organization incorporated in 2019. Its main activity is: Activities of other membership organisations n.e.c.. Its registered office is in Woluwe-Saint-Lambert.
Source: Belgian Official Gazette